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Data collected in a prospective observational research of patients implanted with a cardiac implantable electrical
device (CIED) were analysed. We included 2398 patients: 489 (20.4%) were female and 1909 (79.6%) were male
(oral anticoagulants treatment in 23.2%, independent of gender). During the follow-up (mean 42.8, median 37.7
months), 26 thromboembolic events occurred in 22 patients, with an incidence rate ratio of both stroke and
stroke/transient ischemic attack (TIA) significantly higher in females compared with males [2.00, 95% confidence
interval (CI) 1.53–2.61, P< 0.001 for stroke; 1.77 (95% C1.37–2.31, P< 0.001 for stroke/TIA]. An AF burden5 min
was a common finding (44% of patients), with no difference between men and women. The maximum daily AF bur-
den and the time to evolution in permanent AF did not differ according to gender. The results of multivariate Cox
regression showed that female gender, as well as history of CABG, were significant independent predictors of
stroke and female gender was also an independent predictor of stroke/TIA.
...................................................................................................................................................................................................
Conclusions Among patients implanted with a CIED, an AF burden of at least 5 min is a common finding, (44% of patients).
Female patients have a risk of stroke and TIAs that is around two-fold that of male patients, but this increased risk
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In patients with atrial fibrillation (AF), risk stratification for stroke is the
cornerstone of clinical decision making.1 In patients with AF female gen-
der has emerged as a stroke risk factor in many studies and meta-
analyses2 and has been included in the CHA2DS2-VASc score, which is
the stroke risk stratification scheme recommended in most guidelines.1,2
However, there is an age dependency to stroke risk in females, and there
is no significant increase in the overall risk of stroke in female patients
age<65 years with lone AF.2 The precise reasons why female gender in-
creases the thromboembolic risk are not completely known.3,4
The relationship between stroke and AF burden has recently been
the object of growing interest, since AF burden provides an overall
assessment of the amount of time spent in AF, and has been associ-
ated with an increased risk of stroke.5–9 Even if clinical risk stratifica-
tion is based on clinical factors, data from patients implanted with a
cardiac implantable electrical device (CIED) providing continuous
monitoring of the atrial rhythm showed that the maximum daily AF
burden is associated with an increased risk of ischaemic stroke or
transient ischemic attack (TIA), even after adjustment for oral anti-
coagulants use and the CHADS2 score.
10,11 This suggests that meas-
uring daily AF burden may have important clinical relevance8 and
supports the search for specific thresholds of AF burden associated
with a substantial increase in the risk of ischaemic stroke.6,7,11 Indeed,
AF burden can improve the predictive value of clinical risk scores,
such as CHADS2, for stroke and thromboembolism.
7
In this analysis, based on data collected in a prospective observa-
tional research of patient with a CIED we tested the hypothesis that
the increased thromboembolic risk in female patients may be related
to a higher burden of AF, by comparing the maximum AF daily bur-
den in men and women during long-term follow-up.
Methods
Project design and patient population
Patients participating to the Italian ClinicalServiceVR Project
[ClinicalTrials.gov Identifier: NCT01007474],12 a national medical care
project aiming to improve the quality of diagnostic and therapeutic strat-
egies through the use of implantable cardiac devices in clinical practice,
were considered for the present analysis. The project consists of a shared
environment for prospective collection, management, analysis and report-
ing of data from patients in whom Medtronic devices have been implanted.
In the Italian ClinicalService
VR
Project, patients are prospectively fol-
lowed by participating centres according to clinical practice and guidelines
through standard in-hospital visits. An independent scientific committee
of physicians prospectively identifies key clinical questions on a yearly
basis for analysis and publication. A charter assigns the ownership of data
to the centres and governs the conduct and relationship of the scientific
committee and Medtronic. The project was approved by each site’s
Medical Ethics Committee or Medical Director and conforms to the prin-
ciples outlined in the Declaration of Helsinki. Each patient provided in-
formed consent for data collection and analysis.
For the present analysis, patients were included if they had a CIED
with an atrial lead, had not permanent atrial tachyarrhythmia/atrial fibrilla-
tion (AT/AF), had a clinical follow-up duration of at least 183 days or
more, and had device data continuously stored during the observation
period.
Research objectives
The main research objective was to evaluate whether the thrombo-
embolic risk in female patients may be related to AF burden or other pa-
tients characteristics.
The main endpoint was the incidence of any thromboembolic event, stroke
or TIA. Secondary endpoints were incidence of stroke, daily AF burden, esti-
mated as the number of minutes of AF recorded in a day. The sensitivity and
specificity of device detection of AF burden in Medtronic devices have been
established in previous studies and has been shown to exceed 95% for both
measures.13 In every patient, the maximum daily AF burden experienced dur-
ing follow-up was analysed, as done previously.11 In every patient the max-
imum daily AF burden, as well as the attainment of predefined cut-offs of daily
AF burden (5min, 1h, 6h, 12h, and 23h) and the percentage of days with daily
AF burden beyond predefined cut-offs were assessed. The choice of cut-off
points was based on previously reported thresholds (5min, 6h, and 23h),7,11
thus resulting in multiple cut-off points available for a more complete charac-
terization of the consequences of AF burden. Patients with no AF burden or
less than 5min of AF burden were categorized as not having AF.
During follow-up, patients were considered as having evolved to per-
manent AF if data from the device showed AF (for at least 23 h) during
the last 60 days of the observation period.
Statistical analyses
Baseline patients’ characteristics collected in ClinicalService
VR
case report
forms have been summarized by gender and compared between groups.
Variables on a continuous scale have been described as mean, standard
deviation, median and interquartile range, minimum, and maximum, as ap-
propriate, while variables on a categorical scale were presented as counts
and percentages. Summary statistics were reported with maximum 2
decimals, as appropriate. Continuous variables were compared using the
t-test or the non-parametric Mann–Whitney test, as appropriate depend-
ing on normality of distributions. Comparisons of categorical variables
were performed by means of the Chi-square test or Fisher’s exact test
for extreme proportions, as appropriate.
The distribution of maximum daily burden of AF per patient and the
distribution of the percentage of days with daily AF burden beyond pre-
defined cut-offs per patient were compared between groups by means
of the Mann–Whitney test. To analyse the time to first AF, survival ana-
lysis was carried out by means of the Kaplan–Meier method. Different
curves were compared using the log-rank test. The annual rates of
What’s new?
• In patients with atrial fibrillation (AF), female gender was found
to be a risk factor for stroke, but the reasons for the increased
risk are unknown.
• Among patients implanted with a cardiac implantable electrical
device, we found that a burden of AF of at least 5 min is com-
mon (44% of patients) and that female patients have a risk of
stroke and transient ischemic attacks (TIAs) around two-fold
that of male patients.
• According to our prospectively collected data, the increased
risk of stroke found in female patients cannot be ascribed to a
higher burden of AF, or to differences in the evolution to per-
manent AF.
• Further studies are needed in order to evaluate the reasons
and mechanisms for the increased risk of stroke and TIA asso-
ciated with female gender among patients with AF.
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thromboembolic events were reported [with the 95% Poisson confi-
dence intervals (CI)], and compared between groups using the
Negative binomial model to account for over dispersion of the data.
Predictors of thromboembolic events were found between the base-
line characteristics and the arrhythmia incidence characterizations during
the follow-up (at least one day of daily AF burden beyond pre-defined
cut-offs) by means of the Cox regression.
To account for missingness of baseline data and to ensure enough
power to our analysis, the strategy of multiple imputation has been
chosen. Assuming that observations are missing at random, a fully condi-
tional specification method has been used to impute missing values for all
variables listed in Table 1. Five multiple imputed datasets have been cre-
ated and the research of possible predictors has been performed on each
of them, combining results using appropriate methods. All the imputed
variables have then been tested in univariate Cox regression and those
with a univariate P-value< 0.15 (together with gender which is associated
with the main objective of the analysis) were subsequently put in a multi-
variate Cox regression to identify independent predictors of event. A
complete-case analysis has been performed as sensitivity analysis to con-
firm results obtained on multiple imputed data.
Analyses were carried out using SAS [version 9.3] and a P<0.05 was
considered as statistically significant.
Results
We included 2398 patients, of whom 489 (20.4%) were female and
1909 (79.6%) were male. In Table 1, demographics and baseline charac-
teristics are presented, overall and by gender. As expected, ischemic
heart disease, previous myocardial infarction (MI) and previous revas-
cularization procedures were more common in male patients. The dis-
tribution in categories of CHADS2 score did not show significant
differences between male and female patients. The distribution of
CHA2DS2-VASc score differed between female and male patients, as
expected since female gender is a component of this score. The type
of implanted device was a biventricular implantable cardioverter defib-
rillator (ICD) for cardiac resynchronization therapy (CRT) in 75% of
cases, with dual chamber ICDs more represented in male than female
patients, and dual-chamber pacemakers accounting for< 10% of cases.
The proportion of patients treated with oral anticoagulants (vitamin K
antagonists) was 23%, independent of gender. A history of atrial
tachyarrhythmias was present in approximately the same proportion.
Stroke and stroke/transient ischemic
attack events during follow-up
Patients were followed for a mean follow-up of 436 28 months
(42 6 25 for female and 436 28 for male patients, P¼ 0.874). Median
follow-up interquartile range (IQR) was overall 38 (21–59) months,
being 39 (22–60) for females and 38 (21–59) for males, respectively.
At the end of the observation period, the proportion of patients
treated with an oral anticoagulant (OAC) did not significantly differ
between women (99/489¼ 20.2%) and men (447/1909¼ 23.4%,
P¼ 0.136). During the follow-up period, 26 thromboembolic events
occurred in 22 patients. As shown in Table 2, the incidence rate ratio
of both stroke and stroke/TIA demonstrates that the risk was signifi-
cantly higher in females compared with males.
The results of multivariate Cox regression, that considered
imputed data to account for missing baseline data, showed that
female gender, as well as history of coronary artery by-pass graft
(CABG), were significant independent predictors of stroke (Table 3),
also after correction for oral anticoagulant agent use. In particular fe-
male patients were associated to higher risk of stroke [hazard ratio
(HR)¼ 3.43, 95% CI¼ 1.05–11.18, P¼ 0.041, compared with male
patients] and higher risk of stroke or TIA (HR¼ 2.65, 95%
CI¼ 1.03–6.80, P¼ 0.043, compared with male patients). A second
multivariate model, also including age as a separate variable, con-
firmed that female patients were associated to a higher risk of
stroke or TIA (HR¼ 2.59, 95% CI¼ 1.01–6.67, P¼ 0.049, compared
with male patients), as shown in Supplementary material online
(Table w1 of the supplementary web-only appendix).
Sensitivity analysis
A complete-case analysis was performed to confirm results obtained
on multiple imputed data by applying multivariate Cox regression
analysis on collected data, without data imputation. Results are re-
ported in the supplementary appendix (Supplementary material on
line, Table w2) and confirm the analyses based on imputed data; in
particular female patients were associated to higher risk of stroke
(HR¼ 6.53, 95% CI¼ 1.74–24.55, P¼ 0.005, compared with male
patients) and higher risk of stroke or TIA (HR¼ 5.48, 95% CI¼ 1.
83–16.44, P¼ 0.002, compared with male patients).
Atrial fibrillation burden during follow-up
The proportions of male and female patients achieving different
thresholds of maximum daily burden during follow-up are shown in
Table 4. Overall a daily AF burden of at least 5 min was a common
finding, occurring in 44% of patients.
The time to a maximum daily AF burden 5 min, 1, 6,
and 12 h, respectively, is shown, according to gender, in Kaplan–
Meier curves of Figure 1 and indicates that male patients are associ-
ated with a higher incidence and an earlier occurrence of daily AF
burden durations longer than 6, 12, and 23 h. The time to a daily
maximum AF burden 23 h, 7 days, 30 days and to permanent
AF, respectively, is shown, according to gender, in Kaplan–Meier
curves shown in Figure 2, and shows that attainment of AF burden
durations as long as days or weeks, as well as the time to evolution in
permanent AF did not differ according to gender.
Data on maximum daily AF burden (in hours) and on the percent-
age of days with an AF burden higher than specific thresholds
(Supplementary material online, Tables w3 and w4 of the supplemen
tary web-only appendix) further confirm that the presence and dur-
ation of AF found during follow-up in female patients was not higher
compared to male patients.
Data on maximum daily AF burden (in hours), on the percentage
of patients with an AF burden higher than specific thresholds and on
the percentage of days with an AF burden higher than specific thresh-
olds (Supplementary material online, Table w5 of the supplementary
web-only appendix) show that both the incidence of AF longer than
specified AF durations and the burden of AF were significantly higher
in patients with age 75 years as compared with younger patients.
Maximum AF burden did not show a significant association with
stroke or stroke/TIA at univariate analysis, as shown in Supplementary
material online (Tables w6 and w7 of the supplementary web-only
appendix).














Table 1 Characteristics of the research population at enrolment, according to gender
Variable Total (n52398) Women (n5489) Men (n51909) P-value
Age at device implant Median (IQR) (year) 67.0 (60–74) 68.0 (60– 74) 67.0 (60– 74) 0.169
Hypertension N (%) 1136 (55.8%) 232 (54.2%) 904 (56.2%) 0.456
Diabetes N (%) 483 (23.3%) 91 (20.8%) 392 (24.0%) 0.156
Ischemic heart disease N (%) 1164 (49.1%) 126 (26.0%) 1038 (55.0%) <0.001
Previous MI N (%) 991 (41.8%) 102 (21.0%) 889 (47.1%) <0.001
Previous PTCA N (%) 528 (22.0%) 64 (13.1%) 464 (24.3%) <0.001
Previous CABG N (%) 476 (20.6%) 30 (6.3%) 446 (24.3%) <0.001
Valvular heart disease N (%) 387 (16.1%) 83 (17.0%) 304 (15.9%) 0.574
Valvular surgery N (%) 202 (8.4%) 38 (7.8%) 164 (8.6%) 0.560
Chronic kidney disease N (%) 181 (9.3%) 27 (6.5%) 154 (10.0%) 0.032
COPD N (%) 224 (11.5%) 32 (7.7%) 192 (12.5%) 0.006
History of HF N (%) 1885 (80.3%) 386 (80.1%) 1499 (80.4%) 0.869
Of ischemic aetiology N (%) 814 (34.7%) 88 (18.3%) 726 (38.9%) <0.001
NYHA class 0.127
I N (%) 158 (7.0%) 38 (8.0%) 120 (6.7%)
II N (%) 951 (42.1%) 179 (37.8%) 772 (43.2%)
III N (%) 1111 (49.2%) 246 (51.9%) 865 (48.5%)
IV N (%) 39 (1.7%) 11 (2.3%) 28 (1.6%)
Previous hospitalizations N (%) 790 (42.1%) 164 (41.6%) 626 (42.2%) 0.834
HF hospitalizations N (%) 489 (26.1%) 102 (25.9%) 387 (26.1%) 0.934
History of stroke N (%) 62 (2.9%) 6 (1.3%) 56 (3.3%) 0.025
History of TIA N (%) 44 (2.1%) 12 (2.7%) 32 (1.9%) 0.308
History of Stroke/TIA N (%) 101 (4.7%) 18 (4.0%) 83 (4.9%) 0.411
CHADS2 score 0.756
0 N (%) 108 (5.8%) 25 (6.3%) 83 (5.7%)
1 N (%) 536 (28.9%) 121 (30.7%) 415 (28.4%)
2 N (%) 671 (36.2%) 138 (35.0%) 533 (36.5%)
 3 N (%) 538 (29.0%) 110 (27.9%) 428 (29.3%)
CHA2DS2-VASc score <0.001
0 N (%) 38 (1.8%) 0 (0.%) 38 (2.3%)
1 N (%) 175 (8.4%) 14 (3.1%) 161 (9.8%)
2 N (%) 346 (16.6%) 70 (15.5%) 276 (16.9%)
 3 N (%) 1527 (73.2%) 367 (81.4%) 1160 (70.9%)
History of ventricular arrhythmias N (%) 881 (37.6%) 119 (25.0%) 762 (40.8%) <0.001
History of syncope N (%) 266 (13.4%) 44 (10.9%) 222 (14.0%) 0.107
History of atrial tachyarrhythmias N (%) 544 (22.7%) 109 (22.3%) 435 (22.8%) 0.815
Previous atrial cardioversion N (%) 130 (7.4%) 24 (6.6%) 106 (7.6%) 0.522
ECG findings/diagnosis
LBBB N (%) 1306 (57.0%) 289 (61.0%) 1017 (55.9%) 0.047
Third degree AV block N (%) 161 (7.2%) 38 (8.2%) 123 (6.9%) 0.335
Sinus node disease N (%) 169 (7.4%) 37 (7.8%) 132 (7.2%) 0.655
Echo findings:
LVEF Median (IQR) 28.0 (24–33) 29.0 (25– 32) 28.0 (24–33) 0.451
LVEF<¼0.35 N (%) 1645 (87.9%) 338 (88.3%) 1307 (87.8%) 0.824
Type of implanted device <0.001
DDD/DDDR pacemaker N (%) 80 (3.3%) 32 (6.5%) 48 (2.5%)
Dual-chamber ICD N (%) 505 (21.1%) 73 (14.9%) 432 (22.6%)
CRT-P N (%) 37 (1.5%) 10 (2.0%) 27 (1.4%)
CRT-D N (%) 1776 (74.1%) 374 (76.5%) 1402 (73.4%)
ICD/CRT-D implant for primary prevention N (%) 1828 (82.1%) 381 (89.0%) 1447 (80.5%) <0.001
Pharmacological treatment
ACE-inhibitor/ARB2 N (%) 1759 (81.1%) 347 (80.1%) 1412 (81.3%) 0.569
Continued














Our research conducted in patients implanted with a CIED allowing
continuous monitoring of atrial rhythm, demonstrated that females
have an increased risk of stroke and TIAs during follow-up, but this
increased risk cannot be ascribed to a higher burden of AF. Moreover,
an AF burden of at least 5 min is a common finding in patients implanted
with a CIEDS, in whom the amount of time spent in AF can be precisely
quantified by means of continuous monitoring of atrial rhythm.
Since AF is frequently asymptomatic14,15 and differences in the
ratio of asymptomatic to symptomatic AF episodes have been re-
ported in relation to gender,15,16 use of device-measured AF burden
appears an appropriate method to investigate the relationship be-
tween AF disease burden and the risk of stroke/TIA events. The
ASSERT study found that device detected AF lasting at least 6 min in
duration was associated with a 2.5 fold increase in the risk of ischemic
stroke or systemic embolism over a follow-up of 2.5 years.6 Other
studies have evaluated the relationship between device-detected AF
burden and the risk of stroke and thromboembolism,5,10 but the rela-
tionship between AF burden and gender has not been reported.
Female gender is a risk factor for stroke in AF patients not taking
oral anticoagulants, although there is an age-dependency to this
risk.16 Even if oral anticoagulants are highly effective in reducing the
risk of stroke, some residual risk persists and female gender is among
the factors predictive of the risk of stroke even despite warfarin
treatment.17 In the meta-analysis by Wagstaff et al.3 based on 5
randomized-controlled trials and 12 prospective observational stud-
ies, women with AF were at increased risk of stroke, particularly
women aged75 years, and the relative increase in risk of stroke ap-
peared similar regardless of oral anticoagulation.
The reasons predisposing to an increased risk of stroke in female
patients are still object of debate and a series of factors have been
considered as contributing to the risk of thromboembolism (co-mor-
bidities, hormonal effects, endothelial dysfunction, and prothrom-
botic factors).3 Many factors are involved in the process of
thrombogenesis in AF and can be studied through assessment of a
series of biomarkers.19,20 In a previous study that assessed both bur-
den and biomarkers of thrombogenesis, but did not report on stroke
events, gender was not significantly associated with blood markers
for the hypercoagulable state and blood markers were not correlated
to an increasing amount of AF burden.20
Although assessment of the risk of stroke is based on clinical risk
factors, previous studies found that integration of clinical data with
AF presence/duration/burden may improve risk stratification, thus
providing additional tools on clinical decision making on prescription
of anticoagulants.7,11,21 The impact of anticoagulation therapy on
stroke and thromboembolism, in relation to device detected AF bur-
den, in combination with clinical risk stratification will be prospect-
ively addressed by controlled trials.21 Anyway the determinants of
stroke are complex and it is noteworthy that CHA2DS2-VASC and
CHADS2 scores predict risk of stroke or death in elderly patients
with implanted pacemakers even regardless of AF history.21
....................................................................................................................................................................................................................
Table 1 Continued
Variable Total (n52398) Women (n5489) Men (n51909) P-value
Beta-blocker N (%) 1697 (78.2%) 352 (81.3%) 1345 (77.5%) 0.085
Diuretic N (%) 1819 (83.9%) 372 (85.9%) 1447 (83.4%) 0.195
Amiodarone N (%) 524 (24.2%) 77 (17.8%) 447 (25.7%) <0.001
Anti-platelet N (%) 1047 (48.3%) 178 (41.1%) 869 (50.1%) <0.001
OAC N (%) 503 (23.2%) 100 (23.1%) 403 (23.2%) 0.958
OAC/anti-platelet N (%) 1457 (67.2%) 264 (61.0%) 1193 (68.7%) 0.002
For each patient, characteristic percentages are estimated on patients with collected data for that characteristic.
IQR, interquartile range; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; COPD, chronic obstructive pul-
monary disease; HF, heart failure; NYHA, New York Heart Association; TIA, transient ischemic attack; ECG, electrocardiogram; LBBB, left bundle branch block; AV, atrio ven-
tricular; LVEF, left ventricle ejection fraction; DDD, dual chamber pacing; DDDR, dual chamber pacing with rate response; CRT-P, cardiac resynchronization pacemaker; CRT-
D, cardiac resynchronization defibrillator; ACE, angiotensin-converting-enzyme; ARB2, angiotensin II receptor blockers; OAC, oral anticoagulant.
....................................................................................................................................................................................................................
Table 2 Stroke and TIA events during follow-up according to gender
Variable Women Men
Stroke 5/489 (1.02%) 10/1909 (0.52%)
Stroke/TIA 8/489 (1.64%) 14/1909 (0.73%)
Exposure time (years) 1714 6844
Rate of stroke per 100 pt/year (95% CI) 0.29 (0.12–0.70) 0.15 (0.08–0.27)
Rate of stroke/TIA per 100 pt/year (95% CI) 0.47 (0.23–0.93) 0.26 (0.17–0.42)
Incidence rate ratio female/male for stroke (95% CI) 2.00 (1.53–2.61) P<0.001
Incidence rate ratio female/male for stroke/TIA (95% CI) 1.77 (1.37–2.31) P<0.001
CABG, coronary artery bypass graft; CI, confidence interval; TIA, transient ischemic attack.
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Figure 1 Time to first day with a maximum daily AF burden 5 min, 1, 6, and 12 h, according to gender.
....................................................................................................................................................................................................................
Table 4 Proportion of patients with at least 1 day during follow-up with daily AF burden beyond specified thresholds
of AF burden duration
Variable Overall (n52398) Women (n5489) Men (n51909) P-value
At least 1 day with AF daily burden  5 min 43.7% (1049) 40.7% (199) 44.5% (850) 0.128
At least 1 day with AF daily burden  1 h 35.3% (846) 31.5% (154) 36.2% (692) 0.050
At least 1 day with AF daily burden  6 h 27.1% (649) 22.5% (110) 28.2% (539) 0.011
At least 1 day with AF daily burden  12 h 22.5% (540) 18.6% (91) 23.5% (449) 0.020
At least 1 day with AF daily burden  23 h 18.2% (436) 14.1% (69) 19.2% (367) 0.009
At least 7 consecutive days with AF daily burden  23 h 13.3% (319) 11.2% (55) 13.8% (264) 0.134
At least 30 consecutive days with AF daily burden  23 h 10.7% (257) 8.8% (43) 11.2% (214) 0.123
Chronic permanent AF 5.5% (132) 4.3% (21) 5.8% (111) 0.189
AF, atrial fibrillation.
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In our research, an AF burden of at least 5 min was found in 44% of
patients during follow-up and this stresses that device-detected AF is
a common finding in CIED patients, even independently on previous
history of AF. In literature, both prevalence and incidence of device
detected atrial tachyarrhythmias are variable, depending on underly-
ing heart disease, indication to device implant, time of observation,
and previous history of clinically overt AF. In the ASSERT study, sub-
clinical atrial tachyarrhythmias with at least 6 min duration were de-
tected within 3 months in around 10% of patients implanted with a
CIED6 and in a 2.5-year follow-up additional subclinical atrial tachyar-
rhythmias occurred in around 25% of patients, with around 16% pa-
tients developing a symptomatic AF.6
As mentioned, several studies have found a significant associ-
ation between device-detected AF burden and the risk of stroke
and thromboembolism.5–6,11 According to us, the observation that
female CIED patients had a higher stroke risk compared with male
subjects, but not a higher AF burden, did not necessarily contradict
the positive relationship between AF burden and stroke frequently
reported in the literature. Indeed we know that stroke risk cannot
only and simply be associated to AF burden but rather to many
clinical aspects, such as patient status and comorbidities, left atrium
electrical and structural remodelling, and also other unknown
factors.
The present research reflects real life and is related to patients im-
planted with a CIED and with history of heart failure in the large ma-
jority of cases. In view of the characteristics of this analysis, some
limitations are evident, conditioning potential residual confounding.
The absolute event rate of ischemic stroke was low, probably reflect-
ing a general trend towards lower rates of strokes and TIAs as com-
pared to those predicted by CHADS2 scores. The risk of ischemic
stroke can be reduced by the use of anticoagulants, but we ac-
counted for use of anticoagulants in our multivariable model. The
diagnosis of TIA and stroke was that of daily clinical practice, in line
with the observational nature of this research.
Figure 2 Time to attainment of an AF burden duration 23 h, 7 days, 30 days and to permanent AF according to gender.














In a population of patients implanted with a CIED, an AF burden of at
least 5 min is a common finding, occurring in 44% of patients. Females
with a CIED have a risk of stroke and TIAs during follow-up that is
around two-fold that of males, but this increased risk cannot be
ascribed to a higher burden of AF or to differences in the evolution
to permanent AF. Further studies are needed in order to evaluate
the reasons for the increased risk of stroke and TIA associated with
female gender in subjects with AF.
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